Behaviour of breast cancer molecular subtypes through tumour progression

Clinical and Translational Oncology

Volumn 14, Issue 6, 2012, Pages 481-485

  Castaneda, Carlos A ^a   Andrés, Eva ^b   Barcena, Carmen ^b   Gómez, Henry L ^a   Cortés Funés, Hernán ^b   Ciruelos, Eva ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Breast cancer; Grade; HER2; Lymph node; Metastases; Primary; Size; Subtypes; Variation

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST CANCER MOLECULAR SUBTYPE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PATIENT CODING; PRIMARY TUMOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84864683460     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0827-x     Document Type: Article

References (25)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
2. Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636
3. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187
4. Contesso G, Mouriesse H, Friedman S et al (1987) The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5:1378-1386
5. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
6. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
7. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
8. Gomez HL, Castaneda CA, Vigil CE et al (2010) Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Hematol Oncol Stem Cell Ther 3:109-115
9. Tavassoli FA, Devilee P (eds) (2003) Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: World Health Organization classification of tumours. IARC Press, Lyon
10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410. Comment in 2002;41:151-153
11. Rosen PP, Oberman HA (1993) Tumors of the mammary gland. In: Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC
12. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
13. Mallmann P (2006) [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study]. Internist (Berl) 47:1183-1185
14. Foulkes WD, Grainge MJ, Rakha EA et al (2009) Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 117:199-204
15. Gonzalez-Angulo AM, Litton JK, Broglio KR et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706
16. Chia S, Norris B, Speers C et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704
17. Dent R, Hanna WM, Trudeau M et al (2009) Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 115:4917-4923
18. Bogina G, Bortesi L, Marconi M et al (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459:1-10
19. Singletary SE, Greene FL (2003) Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21:53-59
20. Curigliano G, Viale G, Bagnardi V et al (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699
21. Burstein HJ, Winer EP (2009) Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673
22. Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165
23. Hernandez-Aya LF, Chavez-Macgregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628-2634
24. Comen EA, Norton L, Massague J (2011) Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. J Clin Oncol 29:2610-2612
25. Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer: a reappraisal. Nat Rev Clin Oncol 7:348-353